NiKang Therapeutics
Clinical-stage biotechnology company focused on discovery and development of small-molecule oncology therapeutics. Uses disease-biology-driven target selection and structure-based drug design to address difficult-to-drug targets and has advanced multiple small molecules into first-in-human clinical testing.
Industries
Nr. of Employees
medium (51-250)
NiKang Therapeutics
Patents
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
US-12415779-B2
View DetailsTetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12391642-B2
View Details2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2
View DetailsTetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-11753366-B2
View Details
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
US-12415779-B2
View DetailsTetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12391642-B2
View Details2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2
View DetailsTetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-11753366-B2
View DetailsProducts
NKT2152
Orally available small-molecule inhibitor targeting HIF2α discovered by structure-based design; demonstrated tumor growth inhibition in multiple solid tumor xenograft models and evaluated in Phase 1/2 studies.
NKT3964
First-in-class, orally bioavailable PROTAC degrader designed for selective degradation of CDK2; evaluated in Phase 1 clinical studies for advanced or metastatic solid tumors.
NKT5097
First-in-class, orally bioavailable dual degrader targeting CDK2 and CDK4 designed to simultaneously inhibit CDK2 and CDK4 pathways; under clinical evaluation as single agent and in combination with endocrine therapy.
NKT2152
Orally available small-molecule inhibitor targeting HIF2α discovered by structure-based design; demonstrated tumor growth inhibition in multiple solid tumor xenograft models and evaluated in Phase 1/2 studies.
NKT3964
First-in-class, orally bioavailable PROTAC degrader designed for selective degradation of CDK2; evaluated in Phase 1 clinical studies for advanced or metastatic solid tumors.
NKT5097
First-in-class, orally bioavailable dual degrader targeting CDK2 and CDK4 designed to simultaneously inhibit CDK2 and CDK4 pathways; under clinical evaluation as single agent and in combination with endocrine therapy.
Expertise Areas
- Oncology small-molecule drug discovery
- Structure-based drug design
- PROTAC degrader development
- Translational research and biomarker-driven patient stratification
Key Technologies
- Structure-based drug design
- PROTAC (targeted protein degradation)
- Oral small-molecule therapeutics
- In vivo xenograft models
News & Updates
Presentation of a CDK2/4 dual degrader for cancer therapy and supporting data presented at SABCS 2025; press release distributed via Business Wire.
Company announced completion of dosing of the first cohort in a Phase 1 study of a CDK2/4 dual degrader; press release on Business Wire.
Company completed dosing of the first cohort in a Phase 1 study of a CDK2 PROTAC degrader; press release on Business Wire.
Announcement of first patient dosed in a Phase 1b/2 combination study evaluating an HIF2α inhibitor with standard-of-care for hepatocellular carcinoma; press release on Business Wire.
Presentation of a CDK2/4 dual degrader for cancer therapy and supporting data presented at SABCS 2025; press release distributed via Business Wire.
Company announced completion of dosing of the first cohort in a Phase 1 study of a CDK2/4 dual degrader; press release on Business Wire.
Company completed dosing of the first cohort in a Phase 1 study of a CDK2 PROTAC degrader; press release on Business Wire.
Announcement of first patient dosed in a Phase 1b/2 combination study evaluating an HIF2α inhibitor with standard-of-care for hepatocellular carcinoma; press release on Business Wire.